Cancer Treatment Approaches

Stanford scientists have discovered that cancer cells don’t just use one trick to hide from the immune system—they use two separate “don’t-eat-me” signals to stop macrophages from killing them. The first signal, CD47, was already famous for acting like an invisibility cloak that tells macrophages to back off, and blocking it with an anti-CD47 antibody is already in human trials. In the Nature Immunology paper, the same Stanford team also found that tumors use MHC class I as a second stop signal by binding to a macrophage receptor called LILRB1, which suppresses the macrophage’s ability to engulf and destroy the cancer. When researchers blocked both CD47 and LILRB1 in mice, tumors rapidly filled with immune cells, shrank significantly, and became far easier for the body to clear. This shows that many cancers survive by running two overlapping escape systems, and turning off both “don’t-eat-me” pathways at once may dramatically boost the immune system’s ability to attack and eliminate tumors.

Something remarkable — and rather unsettling — has just been uncovered about small cell lung cancer (SCLC). Two independent teams, one in Cologne and the other at Stanford, have shown that SCLC cells don’t just metastasise to the brain; they integrate into it. The cancer forms fully functional synapses, literally wiring itself into neural circuits and feeding on the brain’s own electrochemical signals. This isn’t metaphorical. Using neurobiological tracers like the rabies virus, researchers demonstrated that neurons and SCLC cells exchange signals through true synaptic junctions. These malignant cells exploit neurotransmitters such as glutamate and GABA, using neural signals to trigger calcium surges that drive proliferation. Incredibly, when scientists shone light on these “wired” cancer cells through optogenetic switches, the tumors grew faster — proof that SCLC can interpret electrical activity directly as a growth command. So what does this tell us? First, it explains why SCLC is so aggressive, resistant, and prone to brain spread. Its cells are “born wired” — descendants of pulmonary neuroendocrine cells, which already receive nerve input. When these transform into cancer, they retain that neural dependency and even enhance it. Second, this discovery reframes SCLC not just as a metabolic disease but also as an electrical and signaling one. The nervous system becomes its power grid.And as always, once we understand the mechanism, we can start thinking about ways to interrupt the signal. Both teams have already tested a few neurologic drugs — ones we’ve used safely for decades. Riluzole, the ALS drug that dampens glutamate release, and levetiracetam, a widely used antiseizure medication, curbed tumor growth and substantially extended survival in mouse models. This points to an entirely new therapeutic strategy: cutting the “neural cord” that fuels this cancer using cheap, well‑understood drugs already sitting on our pharmacy shelves. Targeting this “neuro‑fuel line” may complement traditional metabolic approaches that block glycolysis or glutaminolysis. (see my Metro Map) In practical terms, that might mean combining neuronal modulators like riluzole or memantine with metabolic blockers such as metformin, dichloroacetate, or mebendazole — drugs already discussed in my Metro Map for their ability to starve cancer’s adaptive systems. This research is another reminder that cancer isn’t just rogue cell division; it’s communication gone wrong. The more we learn about these “cancer synapses,” the closer we get to disabling them — whether by tweaking metabolic fuels, neurotransmitters, or both. Science has just shown us that SCLC can literally plug itself into the brain. But it also means we may finally have a way to unplug it — using drugs we already know, repurposed with purpose. #riluzole #memantine #levetiracetam #starvecancer

New Insight: Sensory Neurons Directly Fuel Pancreatic Cancer Growth https://lnkd.in/gEyirt5W A fascinating new study uncovers how pancreatic ductal adenocarcinoma (PDAC) cells form pseudo-synaptic connections with sensory neurons—revealing a previously unseen mechanism of tumor progression in an extracerebral cancer. Key Highlights • Cancer–neuron pseudo-synapses identified: PDAC cells physically interface with sensory nerve endings, forming synapse-like structures. • GRIN2D enrichment: These sites accumulate the glutamatergic receptor subunit GRIN2D, making cancer cells highly sensitive to neuron-derived glutamate. • Glutamate as a growth signal: Neuronal glutamate activates GRIN2D-driven pathways that accelerate PDAC growth, invasion, and calcium signaling. • Therapeutic opportunity: Blocking glutamate–GRIN2D signaling at these pseudo-synapses significantly improves survival in pancreatic cancer models. Why this matters: This work provides compelling evidence that peripheral neurons can “wire into” tumors and directly promote cancer progression. Targeting these neuron-cancer communication loops could open new neurobiology-inspired strategies for treating one of the deadliest cancers. Figure Courtesy: Cancer Cell Ihsan Ekin Demir. Technical University of Munich, School of Medicine, Munich, Germany

Small cell lung cancer, an aggressive form of the disease, has been found to hijack the brain’s own wiring to grow faster. Researchers discovered that when these cancer cells spread to the brain, they don’t just sit beside neurons—they actually form synapses, the same electrical connections neurons use to communicate. These signals provide cancer cells with growth-promoting energy, making tumors more invasive and difficult to treat. This phenomenon was previously seen in brain cancers, but it’s the first time scientists have shown lung cancer doing the same thing. In mice, blocking nerve signals sharply reduced tumor formation and slowed early growth, showing just how crucial neural activity is during cancer development. Once tumors were established, however, blocking nerve input had less impact, suggesting cancer becomes less dependent on nerves at advanced stages. In brain tissue from patients, lung cancer cells were found surrounded by neurons, with electrical stimulation making tumors grow larger and spread faster. Even more striking, anti-seizure drugs that block synaptic signaling significantly reduced tumor size in animal models. These findings reveal that lung cancer doesn’t only mimic neurons—it plugs into the brain’s electrical circuits to thrive. Research Paper 📄 PMID: 40931074

Pancreatic Cancer is "Listening" to the Nerves... Pancreatic cancer's lethality is deeply linked to Neural Invasion (NI). Ren et al. pinpoints a dual mechanism for tumor progression involving the N-methyl-D-aspartate receptor signaling pathway: Paracrine/Synaptic Axis: Neuron-derived glutamate acts on the GRIN2D subunit on cancer cells via a "pseudo-synapse," fueling spread and survival. Autocrine Axis: Cancer cells' self-secreted glutamate acts on the GRIN2B subunit. The takeaway? The NMDAR family, specifically GRIN2D, is a high-value, nuanced therapeutic target in PDAC. Developing non-blood-brain-barrier-penetrating GRIN2D inhibitors will have the potential to specifically block this aggressive neural-cancer communication with minimal CNS side effects. A clearer framework for NMDAR-dependent tumor biology paves the way for smarter, less toxic oncological treatments. And, of course, in time the role of the immune system will become clearer in this tumor-neuronal interaction. https://lnkd.in/exCAM6Hg #Oncology #CancerNeuroscience #PrecisionMedicine #Therapeutics #PancreaticCancerResearch #Tumor